Comparison of Pharmacogenomic Testing Results Across Companies


About this study

The purpose of this study is to:

  1. To evaluate whether the genotypic and phenotypic results for a single subject are the same among companies offering pharmacogenomics testing.

  2. To evaluate the consistency among company generated lists of medications stratified into groups regarding usage for a single subject (i.e., “use as directed,” “use with caution,” or “use with increased caution and with more frequent monitoring”).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Healthy subjects

Exclusion Criteria: 

  • History of mental health diagnoses


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Mark Frye, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer